Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
GYRE · against 439 other Healthcare companies of similar size
Ranked #282 of 440 · scores higher than 11% of peers
Bars: peers in each 10-point band of the valuation score159 peers with a valuation score of 0–9, including GYRE · Click a bar to see the companies
Mainly because of its EBITDA yield and earnings yield, which are weaker than most Healthcare peers.
| Metric | GYRE | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 428 reported | -5.6% | 0.4% | 35% | 30% | |
| EBITDA yieldHigher is better · 445 reported | -2.7% | 3.3% | 30% | 50% | |
| Free cash flow yieldHigher is better · 203 reported | -1.5% | -7.5% | 64% | 20% | |
| Book yieldHigher is better · 438 reported | 22.9% | 48.9% | 20% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 282 | 375M USD | 8 | 46 | |
| 282 | 533M USD | 8 | 36 | |
| 282 | 598M USD | 8 | 49 | |
| 282 | 888M USD | 8 | 25 | |
| 282 | 471M USD | 8 | 21 | |
| 282 | 660M USD | 8 | ||
| 282 | 552M USD | 8 | 39 | |
| 282 | 238M USD | 8 | 41 | |
| 282 | 275M USD | 8 | 46 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score